Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06345755 · ClinicalTrials.gov registry record · Phase 1
A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
A Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 1
- Development phase
- 159
- Enrollment target
NCT06345755: Completed Phase 1 study, sponsored by Vertex Pharmaceuticals Incorporated.
NCT06345755 is a Phase 1 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 159 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (165% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06345755, a Phase 1 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 159 participants
- Enrollment target
Study Summary
The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.
Interventions
- DRUG Placebo
- DRUG Midazolam
- DRUG VX-407
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 159 participants |
| Start Date | 2024-04-17 |
| Est. Completion | 2025-06-13 |
| Phase | Phase 1 |
What the finished NCT06345755 record still lists
NCT06345755 is an interventional study that assigns participants to a tested intervention. The registered 159 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (165% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT06345755 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06345755 about?
NCT06345755 is a clinical study titled "A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants". The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.
What is the current status of trial NCT06345755?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 159 participants. The study started on 2024-04-17. Estimated completion is 2025-06-13.
What interventions are being tested in trial NCT06345755?
The interventions under investigation include: Placebo (DRUG), Midazolam (DRUG), VX-407 (DRUG).
Who is sponsoring clinical trial NCT06345755?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06345755's enrollment target sits among peer trials
159 346th of 2000 higher than 1,653 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05267626 · 159 participants · Phase 1
Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer
- NCT06321575 · 159 participants · NA
The Golazo® Peripheral Atherectomy System for a Safe and Effective Atherectomy (GREAT Trial)
- NCT06729151 · 159 participants
Effect of Intradetrusor onabotulinumtoxinA Injection Versus Conservative Management on Female Sexual Function in Patients With Bladder Pain Syndrome
- NCT07023731 · 159 participants · Phase 1
A Study to Evaluate ARV-806 in Adults With Advanced Cancer That Has the KRAS G12D Mutation
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI